Today: 9 June 2026
Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names
30 December 2025
2 mins read

Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

NEW YORK, December 30, 2025, 14:21 ET — Regular session

  • Karman Holdings shares fell in afternoon New York trade, lagging a subdued broader market.
  • Recent outflows from an aerospace and defense ETF have put the spotlight on fund-driven selling pressure.
  • Investors are watching whether the pullback stabilizes ahead of the company’s next quarterly update.

Karman Holdings Inc. shares were down 3.6% at $74.81 in afternoon trading on Tuesday, after touching $74.21 at the session low. The stock traded as high as $78.55, with about 465,000 shares changing hands.

The dip comes in the final week of the year, when thinner liquidity can exaggerate moves in individual stocks. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide, in a broader market note on holiday-thin trading.

Fund flows have also become a near-term focus for aerospace and defense names. Data cited by Nasdaq.com showed the SPDR S&P Aerospace & Defense ETF (XAR) saw an estimated $258.7 million outflow, or a 5.1% week-over-week drop in shares outstanding (from 20,475,000 to 19,425,000). A drop in shares outstanding typically reflects redemptions, meaning the fund can have to sell underlying holdings to meet investor withdrawals.

XAR is designed to track the aerospace and defense segment of the market, giving investors a one-ticket way to buy a basket of contractors and suppliers. State Street, which runs the ETF, says XAR aims to match the performance of the S&P Aerospace & Defense Select Industry Index before fees and expenses.

The sector tape looked steadier than Karman’s move suggested. XAR was down about 0.4% on Tuesday, while the SPDR S&P 500 ETF (SPY) was little changed, underscoring Karman’s sharper slide versus the broader market.

Karman, which does business as Karman Space & Defense, went public in February, when the company and selling shareholders raised $506 million in an upsized IPO that valued the defense and space systems maker at nearly $3 billion, Reuters reported.

In its most recent quarterly update in November, the company reported revenue of $121.8 million, up 41.7% from a year earlier. It also posted funded backlog of $758.2 million — a measure it defined as the invoiceable value of existing contracts, net of what has already been billed.

Karman said it raised and narrowed its full-year 2025 outlook, projecting revenue of $461 million to $463 million and non-GAAP adjusted EBITDA of $142 million to $143 million. Adjusted EBITDA is a profit yardstick that starts with earnings before interest, taxes, depreciation and amortization, then strips out selected items to show underlying operating performance.

The company also laid out a preliminary expectation for 2026 revenue growth of 20% to 25%, excluding future acquisitions. That makes the stock sensitive to shifts in sentiment around defense budgets, space launch spending and the cadence of government-backed programs that feed supplier order books.

In the near term, traders are watching whether Tuesday’s selloff holds near the bottom of the day’s range as year-end portfolio adjustments continue. In stocks with shorter public trading histories, flows — not headlines — can become the dominant driver for stretches of time.

Investors will also be watching for any fresh contract-related updates from primes and program owners that ripple down to suppliers, as well as any new filings that shed light on insider or institutional activity.

Stock Market Today

  • Broadcom Stock Set for 27% Gain to $500 Amid AI Growth, Despite Recent Selloff
    June 9, 2026, 10:08 AM EDT. Broadcom (NASDAQ:AVGO) shares dropped nearly 14% post-earnings despite 47.87% revenue growth and an eighth straight earnings per share (EPS) beat. The stock trades around $396.60, with a 24/7 Wall St. price target of $503.61, implying a 26.98% upside over 12 months and a buy recommendation at 90% confidence. Broadcom's Q2 revenue hit $22.19 billion with a 143% jump in AI semiconductor sales to $10.8 billion. CEO Hock Tan projects over 200% AI revenue growth in Q3, targeting $16 billion. Bear risks include heavy insider selling and a high 64 forward P/E ratio. Bulls note strong AI demand, with price targets up to $600 billion revenue potential by 2028. The stock remains 14.82% higher year-to-date despite recent volatility.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Previous Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Next Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Go toTop